Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 10/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2878572 | 0.83 | HCRTR1 (0.55) | HCRTR1HCRTR2PDE2APDE10A | |
| SCHEMBL29364130 | 0.80 | HCRTR2 (0.60) | HCRTR1HCRTR2GPR119PDE2APDE10A | |
| SCHEMBL2859936 | 0.80 | HCRTR1 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL2880295 | 0.78 | HCRTR1 (0.68) | HCRTR1HCRTR2 | |
| SCHEMBL2858983 | 0.76 | HCRTR2 (0.70) | HCRTR1HCRTR2 | |
| SCHEMBL23560705 | 0.74 | GPR119 (0.61) | MAP4K4GPR119NTRK1MAPTHDAC1 | |
| SCHEMBL13106108 | 0.74 | HCRTR1 (0.46) | HCRTR1HCRTR2PDE2APDE10AMAPT | |
| SCHEMBL20158931 | 0.74 | GPR119 (0.61) | MAP4K4GPR119NTRK1MAPTHDAC1 | |
| SCHEMBL3094896 | 0.72 | MAPT (0.45) | HCRTR1HCRTR2PDE2APDE10AMAPT | |
| SCHEMBL20141579 | 0.71 | GRM1 (0.61) | MAP4K4GPR119NTRK1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362009-B2 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362009-B2 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2214676-B1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-11-21 | — | — | EP | disclosed |
| EP-2214676-B1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20100256121-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256121-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| EP-2214676-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009058238-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058238-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256121-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885MAP4K4 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.